Market capitalization | $17.02b |
Enterprise Value | $21.96b |
P/E (TTM) P/E ratio | 20.63 |
EV/FCF (TTM) EV/FCF | 25.10 |
EV/Sales (TTM) EV/Sales | 2.35 |
P/S ratio (TTM) P/S ratio | 1.82 |
P/B ratio (TTM) P/B ratio | 2.57 |
Dividend yield | 1.86% |
Last dividend (FY23) | $2.84 |
As a Free StocksGuide user, you can view scores for all 6,914 stocks worldwide.
20 Analysts have issued a Quest Diagnostics forecast:
20 Analysts have issued a Quest Diagnostics forecast:
Jun '24 |
+/-
%
|
||
Revenue | 9,346 9,346 |
1%
1%
|
|
Gross Profit | 2,973 2,973 |
5%
5%
|
|
EBITDA | 1,807 1,807 |
1%
1%
|
EBIT (Operating Income) EBIT | 1,354 1,354 |
3%
3%
|
Net Profit | 836 836 |
6%
6%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Quest Diagnostics, Inc. engages in the provision fo diagnostic testing, information and services. It operates through the Diagnostic Information Services (DIS) and All Other segments. The DIS segment offers diagnostic information services to patients, clinicians, hospitals, health plans, and employers. The All Other segment consists of risk assessment services, healthcare information technology, diagnostic products, and clinical trials testing businesses. The company was founded in 1967 and is headquartered in Secaucus, NJ.
Head office | United States |
CEO | James Davis |
Employees | 48,000 |
Founded | 1967 |
Website | www.questdiagnostics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.